Immunotherapy added to first-line standard therapy significantly improves survival in metastatic or recurrent cervical cancer
Credit: Vall d'Hebron Institute of Oncology (VHIO). Immunotherapy added to first-line standard therapy significantly improves survival in metastatic ...